MIRA Unveils Promising Results for SKNY-1 in Zebrafish Study

MIRA Pharmaceuticals has announced notable findings from a recent study involving their drug candidate, SKNY-1. In animal models mimicking human obesity and cravings, SKNY-1 demonstrated substantial weight reduction and reversed nicotine cravings. Conducted over six days, the study highlighted a 30% reduction in body weight without muscle loss, suggesting an effective capacity to target fat loss.

SKNY-1, designed as an oral alternative to existing GLP-1 injectables, reportedly circumvents common issues like gastrointestinal side effects. The therapy significantly improved liver fat and cholesterol profiles of treated animals. Additionally, SKNY-1 suppressed high-calorie and nicotine-seeking behaviors, normalizing associated hormonal imbalances and dopamine regulation.

Such results underscore SKNY-1's potential to address two prevalent health issues, boosting its development prospects as MIRA moves towards acquiring SKNY Pharmaceuticals, Inc.